Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer

Share this content:

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer

Sponsors and Collaborators
Swiss Group for Clinical Cancer Research
 
Contact
ClinicalTrials.gov identifier: NCT01005199
 
Investigators
Dieter Koeberle, MD
Kantonsspital - St. Gallen
 
Jean-Francois Dufour, MD
University Hospital Inselspital, Berne
 
Michael Montemurro, MD
Centre Hospitalier Universitaire Vaudois
 
Gyorgy Bodoky, MD, PhD
Szent Laszlo Korhaz
  
ClinicalTrials.gov Identifier

NCT01005199

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs